Carregant...
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
BACKGROUND: Cystic fibrosis (CF) pulmonary exacerbations can be serious respiratory events and reduction in exacerbation rate or risk are important efficacy endpoints for CF therapeutic trials. Variability in exacerbation diagnoses and treatment have led drug developers to employ “objective” exacerb...
Guardat en:
| Publicat a: | J Cyst Fibros |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
European Cystic Fibrosis Society. Published by Elsevier B.V.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7362840/ https://ncbi.nlm.nih.gov/pubmed/32682670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2020.07.008 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|